The IDIAP Jordi Gol
Who we are
Organization
Quality Certification
Strategic plan
Annual reports
HRS4R
Transparency
Research
Territorial Support Units (USR)
Research Areas
Publications
Projects
CEIm
CEIM presentation
How to Submit the Documentation to the CEIM
Rates of The CEI
CEI meeting calendar
Regulations and links of interest CEI
Services and Platforms
Grants to Finance Research
Clinical Trial Monitoring
Platforms Questionnaires
Sidiap Database
Real World Lab
Tools-Help
Scientific Tools
Management Tools
IDIAP Management Tools
Innovation
News
Enllaç al GIR
Acces GIR
Login
Català
Castellano
English
The IDIAP Jordi Gol
Who we are
Organization
Quality Certification
Strategic plan
Annual reports
HRS4R
Transparency
Research
Territorial Support Units (USR)
Research Areas
Publications
Projects
CEIm
CEIM presentation
How to Submit the Documentation to the CEIM
Rates of The CEI
CEI meeting calendar
Regulations and links of interest CEI
Services and Platforms
Grants to Finance Research
Clinical Trial Monitoring
Platforms Questionnaires
Sidiap Database
Real World Lab
Tools-Help
Scientific Tools
Management Tools
IDIAP Management Tools
Innovation
News
Enllaç al GIR
Cercador
ELS MÉS BUSCATS
COL·LABORA
Menú
English
Català
Español
Home
USR Barcelona
USR Barcelona
RESPONSABLE
Daniel Martínez Laguna
dmartinezl.bcn.ics@gencat.cat
Presentation
Team
Groups
Publications
Projectes
News
Presentation
Team
Groups
Publications
Projectes
News
Projectes
Group projects
Patient characteristics and cardiovascular and mortality outcomes in patients with high cardiovascular risk and type 2 diabetes mellitus initiating treatment with sodium-glucose co-transporter-2 inhibitors and other antidiabetic medications
Principal investigators:
Josep Franch Nadal
Code:
4R17/071
Start year:
2017
Funders:
AstraZeneca Farmacéutica Spain, S.A.
Global and country-specific rates and trends in the incidence of diagnosed type 2 diabetes (GLOBALDIAB)
Principal investigators:
José Manuel Mata Cases
Code:
4R17/084
Start year:
2017
Funders:
ICS - Institut Català de la Salut
Estudio sobre los resultados de la adición de una sulfonilurea, un iDPP4 o un iSGLT2 como segundo antidiabético en pacientes con DM2 en tratamiento con metformina e insuficiente control glucémico. Estudio eControl Metf+
Principal investigators:
Josep Franch Nadal
Code:
4R17/101
Start year:
2017
Funders:
AstraZeneca Farmacéutica Spain, S.A.
All-cause and cardio-renal-metabolic mortality in people with type 2 diabetes: a comparative international trend study.
Principal investigators:
Dídac Mauricio Puente, Dídac Mauricio Puente
Code:
4R19/014
Start year:
2019
Funders:
University of Leicester
Descubrimiento y validación de marcadores de predicción de diabetes tipo 2: proyecto colaborativo de cohortes.
Principal investigators:
Dídac Mauricio Puente
Code:
4R19/120
Start year:
2019
Funders:
Instituto de Salud Carlos III
Anterior
1
…
18
19
20
21
22
…
211
Següent